Subject Index

Acidosis, see Metabolic acidosis
Activated carbon, sorbents 337
Adipokines
  adipose tissue and systemic inflammation 169
  functions 167–169
  prospects for study in renal patients 171
Adiponectin, functions 168
Advanced glycation end products (AGE)
  animal models of peritoneal dialysis 72, 73
  formation 78, 79, 91
  malnutrition-inflammation-atherosclerosis syndrome prevention 140
  peritoneal dialysis accumulation 49–51, 77
  receptor, see RAGE
Albumin, serum levels and mortality risks 152, 153
Anemia
  etiology 205
  prevalence in peritoneal dialysis 202
  treatment
    dialysis adequacy 206
    erythropoiesis-stimulating therapy administration route 208, 211
    darbepoetin alfa 207, 208
    epoetin alpha 207, 208
    epoetin beta 207, 208
    expected response 208
    poor response 209, 210
    initiation 203
    iron replacement 206, 207
    nutrition 206
    peritonitis patients 210, 211
    target hemoglobin concentration 203–205
Angiogenesis, see Vascular endothelial growth factor
Angiotensin II, peritoneal dialysis induction and fibrosis 74
Angiotensin-converting enzyme (ACE) inhibitors
  malnutrition-inflammation-atherosclerosis syndrome prevention 141
  mesothelial cell effects 163
  renal function preservation after failed kidney transplant 275
Antibiotics
  malnutrition-inflammation-atherosclerosis syndrome prevention 141, 142
  peritonitis management 183
Aquaporin-1, peritoneum 33, 34, 98, 99
Atherosclerosis, see Malnutrition-inflammation-atherosclerosis syndrome; Vascular calcification
Automated peritoneal dialysis (APD)
  adequacy targets 281, 282, 285, 286
  cyclers
    Home Choice 295
    Home Choice Pro 295, 296
    ideal criteria 300
    overview 294
    PD 100T 298
Calcium handling
  calcium balance in peritoneal dialysis 219, 220
  control in peritoneal dialysis 221, 222
  phosphorus balance in peritoneal dialysis 220, 221
  renal osteodystrophy 218, 219
  serum levels and mortality risks 214
  vascular calcification
    impact in dialysis patients 217, 218
    pathogenesis 215–217
    risks 215
Cardiovascular disease, chronic kidney disease 144, 145
Catheters, see also Tenckhoff catheter
  continuous-flow peritoneal dialysis 313
  designs 198
  double-lumen catheters for continuous-flow peritoneal dialysis 199
  historical perspective 195–197
Cbfa-1, vascular calcification role 216
Cloudy dialysate
  diagnostic algorithm 192, 193
  infection 187
  noninfectious causes
    eosinophils 190
    fibrin 192
    malignant cells 191
    monocytes 190, 191
    overview 187–189
    polymorphonuclear leukocytes 189, 190
    red blood cells 191
    triglycerides 192
Congestive heart failure
  comorbidity 248
  epidemiology 130, 247
  fluid overload 129
  hemodialysis treatment 132, 249
  hemofiltration therapy 249
  medical management 131
  mortality 248
  pathophysiology 130, 131
  peritoneal dialysis treatment of refractory disease 132, 133, 249–252, 333, 334
  pharmacotherapy 248
  stages 130
Continuous cycling peritoneal dialysis, see Automated peritoneal dialysis
Continuous flow peritoneal dialysis (CFPD)
catheter design 313
dextrose as osmotic agent 314
dialysis adequacy 311–313
monitoring 314, 315
rationale 310, 311, 317, 322–324
safety 315
scheduling 323, 324
ultrafiltration control 313, 314
urea kinetics 315, 316
Convection
hemodialysis 1–3
interference with diffusion 6
C-reactive protein (CRP)
cardiac event prediction 153
inflammation marker 136, 145–147
mortality prediction 153, 158
Darbepoetin alpha, see Anemia
Dialysate
cloudy, see Cloudy dialysate
regeneration with sorbents 340
Dialysis fluids
automated peritoneal dialysis
composition 304, 305
on-line preparations 305, 306
bicarbonate-based solutions in bone
disease treatment and prevention 222
combinations of biocompatible fluids
94, 95
glucose-containing biocompatible fluids
Balance 91, 92
Gambrlosol Trio 91
Physioneal 92, 93
inflammation prevention 147, 148
low glucose degradation product solutions
and biocompatibility 162, 163
malnutrition-inflammation-atherosclerosis
syndrome prevention 140
mesothelial cell phenotype and
peritoneal dialysis response 159, 160
non-glucose-containing biocompatible
fluids
Extraneal 94
Nutrineal 93, 94
pH effects on inflammation 160
Diffusion
hemodialysis 1–3
interference with convection 6
solute transfer in peritoneal dialysis 15, 16
Dry body weight
assessment 105, 106
definition 105
Elderly patients
prevalence of chronic peritoneal dialysis
utilization 240
prospects 244, 245
underutilization of chronic peritoneal
dialysis reasons
compliance 241, 242
dialysis adequacy and nutrition 242, 243
hospitalization 242
infectious complications 242
manual dexterity and neuropsychiatric
function 241
overview 240, 241
patient survival 243, 244
technique survival 243
Eosinophils, cloudy dialysate 190
Epoetin, see Anemia
Extraneal, clinical studies 94, 140
Fetuin, vascular calcification prevention
216, 217
Fibrin, cloudy dialysate 192
Fibrosis, peritoneum
angiotensin II role 74
clinical correlates and mechanisms
178
hydrostatic pressure effects on avascular
matrix 179
inflammation association 176
RAGE role 73, 74, 81
sclerosis etiology and pathogenesis 66, 67
solute clearance effects 179
sub-peritoneal compact zone alterations
176–178
transforming growth factor-β role 73
Gambrosol Trio, clinical studies 91
Glitazone, malnutrition-inflammation-atherosclerosis syndrome prevention 141
Glucose degradation products (GDPs)
- compounds 91
- dialysis fluid as source 77
- inflammation induction 146
- mesothelial cell phenotype and peritoneal dialysis response 161
- peritoneal membrane accumulation and effects 50, 51, 78, 79

Heart failure, see Congestive heart failure

Hemodialysis
- blood compartment 4, 5
- congestive heart failure management 132
- convection 1–3, 6
- dialysate compartment 5
- diffusion 1–3, 6
- kidney transplant outcome effects, see Kidney transplant
- membrane permeability 3, 4
- peritoneal dialysis integration in uremia treatment, see Uremia
- solute clearance factors 2
- solute diffusivity and sieving 3–5
- urea kinetics modeling, see Urea kinetics

Home Choice, automated peritoneal dialysis cycler 295
Home Choice PRO, automated peritoneal dialysis cycler 295, 296

Hyaluronan, peritoneal transport effects 162

Hyperphosphatemia, see Phosphate handling

Icodextrin, peritoneal dialysis use
- metabolism 100
- overview 45, 94, 97
- peritoneal transport with solutions clinical studies 101
- high transporter patient use 101, 102
- long-term effects 102
- ultrafiltration 100, 101
- structure 100

Inflammation, see also Malnutrition-inflammation-atherosclerosis syndrome
- adipose tissue and systemic inflammation 169
- etiology in peritoneal dialysis 145, 146, 167
- genetic susceptibility 147
- glucose degradation product induction 146
- markers 136, 145, 153, 167
- pathophysiology in peritoneal dialysis 160, 161
- peritoneal dialysis failure role 156
- prevention in peritoneal dialysis 147–149
- Interleukin-6 (IL-6), gene polymorphisms 47, 158
- Intravital microscopy, peritoneum
  - acute effects of peritoneal dialysis fluid perfusion 86, 87
  - chronic dialysis fluid exposure studies 87, 88
  - glucose effects in diabetic rat model 86
  - technique 86

Iron, anemia management 206, 207

Kidney transplant
- failure rate 271, 272
- patient selection for renal replacement therapy mode 261
- peritoneal dialysis after failed transplant hemodialysis comparison 272, 273
- immunosuppressive therapy 274, 275
- recommendations 275, 276
- residual renal function preservation 274, 275
- technique failure 273, 274
- peritoneal dialysis penetration and technique survival 260, 261
- renal replacement therapy mode effect on outcomes
  - cold ischemia time 261

combined kidney and pancreas transplantation after peritoneal dialysis 256
- immediate post-transplant graft function 254–256, 262–264
- long-term graft and patient survival 256, 257, 266, 267
- vascular thrombosis 264–266

Subject Index 349
Knockout mouse, see RAGE
Kt/V, see Urea kinetics

Leptin, functions 167, 168

Macrophage, adipocyte interactions 169
Malnutrition-inflammation-atherosclerosis (MIA) syndrome
atherosclerosis 137
inflammation markers 136
malnutrition 136, 137
metabolic acidosis 138
overview 135
peritoneal transport 137
residual renal function 137, 138
treatment
angiotensin-converting enzyme inhibitors 141
antibiotics 141, 142
biocompatible peritoneal dialysis solutions 140
glitazone 141
inflammation nutrition 139
volume control 139
lifestyle modification 142
malnutrition
acidosis 138, 139
appetite stimulants 139
dialysis adequacy 138
nutritional support 138
nonsteroidal anti-inflammatory drugs 141
statins 141
thalidomide 142
vitamin C 141
vitamin E 141
Matrix GLA protein (MGA), vascular calcification prevention 216, 217
Mesothelial monolayer
animal model of peritoneal dialysis effects
dialysis solution studies of repopulation and repair 57–59
homeostatic repopulation 57
preparation 55
cell phenotype and peritoneal dialysis response 49, 156, 157, 159–161

glucose degradation product effects 78, 79

Metabolic acidosis
bicarbonate-based solutions in treatment and prevention 222
bone metabolism effects in peritoneal dialysis 222
malnutrition-inflammation-atherosclerosis syndrome 138
Monocytes, cloudy dialysate 190, 191
Multifrequency bioimpedance analysis (MF-BIA), see also Bioimpedance analysis
dry body weight assessment 105, 106
personal impedance analyzer applications 332–334
overview 328, 329
study design 329
validation 330, 332
principles 122

Nonsteroidal anti-inflammatory drugs (NSAIDs), malnutrition-inflammation-atherosclerosis syndrome prevention 141
Normalized protein equivalent of nitrogen appearance (nPNA), calculation and urea clearance relationship 20, 21
Nutrineal, clinical studies 93, 94, 140

Osteopontin, vascular calcification prevention 216

Overhydration
causes 113
diagnosis 112, 113
peritoneal dialysis complication 111, 112
prevalence 112
treatment
hypertonic glucose 114
peritoneal ultrafiltration 114, 115
residual renal function and diuresis effects 114, 115
sodium restriction 113, 114

Patient On Line (POL), peritoneal function testing 39
PD 100T, automated peritoneal dialysis cycler 298
PD 101, automated peritoneal dialysis  
cycler 298
PD 200, automated peritoneal dialysis  
cycler 298, 299
PD-Adequest, peritoneal function testing  39
PD Night, automated peritoneal dialysis  
cycler 296, 297
Peritoneal dialysis, see also Automated  
peritoneal dialysis; Continuous flow  
peritoneal dialysis
access, see Catheters
animal models  
acute models  72
ANIMOD collaboration  70, 71
chronic models  72–74
clinical relevance  71, 72
prospects  74
dialysis solutions, see Dialysis fluids
failure rate  45
initiation  42–46
kidney transplant outcome effects, see  
Kidney transplant
long-term effects on peritoneal function  
glucose degradation product  
accumulation  48–51
mesothelium effects, see Mesothelial  
monolayer
overview  17
sclerosis, see Sclerosis, peritoneum
lymphatic absorption  16
modes  43
solute transfer  
convection  16
diffusion  15, 16
solute transport factors  
dialysate compartment  6–8
membrane properties  8, 9
microcirculation  9–11
sorbents, see Sorbents
urea kinetics modeling, see Urea kinetics
Peritoneal equilibration test (PET)  
chronic peritoneal dialysis findings  157
peritoneal function testing  37, 38, 40
Peritoneum  
anatomy  13, 14, 31–33
aquaporin-1  33, 34
cellular immune response  158, 159
fibrosis, see Fibrosis, peritoneum
function  14
interstitium  
structure  175
transport role  175, 176
membrane  
function testing  17, 37–40
properties  8, 9
vascular bed studies, see Intravital  
microscopy, peritoneum
microcirculation  9–11, 33
resistance to solute and water transport  
14, 15
sclerosis, see Sclerosis, peritoneum
ultrafiltration, see Ultrafiltration,  
peritoneum
Peritonitis  
anemia management  210, 211
catheter removal  184, 185
causes  182, 183
clinical presentation  182
cloudy dialysate, see Cloudy dialysate
epidemiology  181, 182
fungal peritonitis  183, 184
management  183
mortality  181
mycobacterial peritonitis  184
peritoneal dialysis risks  45, 50, 51
sclerosis etiology  66
Personal Dialysis Capacity test (PDC),  
peritoneal function  39, 40
Personal impedance analyzer (PIA)  
applications  332–334
overview  328, 329
study design  329
validation  330, 332
Phosphate handling  
calcium balance in peritoneal dialysis  
219, 220
calcium control in peritoneal dialysis  221, 222
phosphorus balance in peritoneal dialysis  
220, 221
serum levels and mortality risks  214, 215
vascular calcification  
impact in dialysis patients  217, 218
pathogenesis  215–217
risks  215
Sodium
  dietary intake recommendations 108
  removal in peritoneal dialysis 108
  mortality relationship 108
  target 106, 107
Sorbents
  activated carbon 337
  dialysate regeneration 340
  peritoneal dialysis utilization 340, 341

Physioneal, clinical studies 92, 93, 140
Pit-1, vascular calcification role 216
Polymorphonuclear leukocytes, cloudy
dialysate 189, 190

RAGE
  knockout mouse studies
  peritoneal angiogenesis 80, 81
  peritoneal fibrosis 81
  peritoneal inflammation 80
  ligands 79, 80
  mesothelial cell effects 78, 79
  peritoneal fibrosis role 73, 74
  signal transduction 79, 80
  structure 79
Red blood cells, cloudy dialysate 191
Residual renal function (RRF)
  kidney transplant failure and preservation
    with peritoneal dialysis 274, 275
  malnutrition-inflammation-atherosclerosis syndrome 137, 138
  overhydration treatment effects 114, 115
  prognostic value 153
Resistin, functions 168, 169

Scleroderma, peritoneum
  animal models 65
  etiology and pathogenesis 66, 67
  frequency in peritoneal dialysis 63
  pathology 63–65
  simple sclerosis versus sclerosing
    peritonitis 62, 63, 67
Shear rate value
  blood 4
  solute transfer in peritoneal dialysis 16
Sleep Safe, automated peritoneal dialysis
cycler 297
Subject Index 352
Statins, malnutrition-inflammation-
  atherosclerosis syndrome prevention 141
Tenckhoff catheter
  development 197
  modifications for complication
    avoidance 197–199
Thalidomide, malnutrition-inflammation-
  atherosclerosis syndrome prevention 142
Transforming growth factor-β (TGF-β)
  glucose degradation product induction 78
  peritoneal dialysis induction and fibrosis
    73
  peritoneal membrane effects 85
Triglycerides, cloudy dialysate 192
Ultratransmission, peritoneum
  automated peritoneal dialysis 282, 283
  continuous flow peritoneal dialysis
    control 313, 314
  fluid loss measurement 31
  intraperitoneal hydrostatic pressure 31
  lymph flow measurement 31
  membrane model 29
  net ultrafiltration
    equation 28
    osmosis and fluid loss 29, 30
    prospects for study 34, 35
    overhydration treatment effects on
      residual renal function and diuresis
        114, 115
    overview 16
    transport process 98–100
Urea kinetics
  blood urea versus blood urea nitrogen 23
  clearance in normal kidney 21, 22
  continuous flow peritoneal dialysis 315, 316
  hemodialysis
    overview 22
    simplified model
      peritoneal dialysis comparison 26